Richard S. Finn, MD

GI Oncology Now

<p>Richard Finn, MD, of the Geffen School of Medicine at UCLA, provides an update on recent developments in hepatocellular carcinoma treatment (HCC), highlighting key findings from studies involving immune checkpoint inhibitors targeting CTLA-4 and PD-1 pathways. Dr. Finn explains how the inclusion of patients with main portal vein invasion impacts outcomes in overall survival.</p>


Emily Menendez

OS Rates Similar for Irinotecan Monotherapy and Combination in Advanced Gastric Cancer

Gastric Cancer

Laura W. Goff, MD

From Frontline to Adjuvant: Dr. Laura Goff on the Expanding Role and Limits of Immunotherapy in HCC

Liver Cancer

Scott Kopetz, MD, PhD

BREAKWATER Advances: Dr. Scott Kopetz on First-Line Therapy for BRAF V600E-Mutated mCRC

Colorectal Cancer

Latest News

ESMO 2024 Key Highlights in Liver Cancer: LEAP-012 and IMbrave050 Discussion

Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.